Sign In
Buy ABSI
$5.94
-0.410 (-6.46%)
At Close: Jun 03, 2026
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
10:43am, Monday, 05'th Feb 2024
Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
07:30am, Wednesday, 10'th Jan 2024
VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene
Absci to Participate in the 26th Annual Needham Growth Conference
08:00am, Wednesday, 03'rd Jan 2024
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 28'th Dec 2023
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
07:30am, Wednesday, 20'th Dec 2023
Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Act
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
09:46am, Tuesday, 05'th Dec 2023
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
07:30am, Monday, 04'th Dec 2023
Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform wi
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
01:28am, Sunday, 03'rd Dec 2023
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times re
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
08:00am, Wednesday, 15'th Nov 2023
VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom
Absci to Participate in Upcoming Investor Conferences
08:00am, Thursday, 26'th Oct 2023
VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the follo
Absci to Participate in Upcoming Investor Conferences
04:05pm, Monday, 28'th Aug 2023
VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the follo
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
03:51pm, Monday, 14'th Aug 2023
Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certai
Beyond OpenAI: 7 promising startups that have saved lives, sped up drug development and improved manufacturing
11:36am, Thursday, 01'st Jun 2023
OpenAI is stealing the spotlight as the definitive artificial-intelligence startup — for now. Backed by Microsoft Corp. MSFT, the progenitor of ChatGPT-4 has become the focus of the AI wave, but oth
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
06:59pm, Monday, 15'th May 2023
Absci Corporation (ABSI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.33 per share a year ago.
